

FINAL Comprehensive Research Plan:

Treatment of Attention Deficit Hyperactivity Disorder in Adults

Environmental Scan

April 27th, 2015

ODPRN Drug Class Review Proposal: Environmental Scan

Study Title: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults

- Objectives:**
1. To summarize the pharmacy benefit programs for drugs for treatment of ADHD (stimulants and non-stimulants) in Ontario, across Canada and in select international jurisdictions
 2. To determine the impact of different drug reimbursement schemes for drugs for treatment of ADHD (stimulants and non-stimulants) on patient access, quality of life and/or utilization and costs
 3. To summarize the guidelines for management of adult patients with ADHD
-

- Study Questions:** In adult patients with ADHD:
1. How are treatment options (stimulants and non-stimulants) currently being accessed in publicly funded programs across Canada as well as internationally?
 2. What is the impact of different drug reimbursement schemes for stimulants and non-stimulants on patient access, quality of life and/or utilization and costs?
 3. Does sex, gender or socioeconomic status play an important role in any of the analyses described?

Objective 1: Pharmacy Benefit Programs in Ontario, across Canada and internationally

Study Design: Design: summary of available information available through the Internet; interviews with individuals at the government agencies responsible for the public drug plan
Data sources: Internet, direct contact with individuals

- Study Population:**
- Canada: provincial/territorial public plans
 - England, Wales, Northern Ireland, Scotland: NICE (National Institute for Health and Care Excellence)
 - Australia: Pharmaceutical Benefits Scheme
 - United States: Medicare, Veterans Affairs
 - New Zealand: PHARMAC (Pharmaceutical Management Agency)
-

- Intervention:**
- Stimulants (amphetamine mixture, dextroamphetamine, lis-dexamfetamine, methylphenidate)
 - Non-stimulants (atomoxetine, guanfacine)
-

- Outcome(s) of Interest:** Drug Reimbursement Criteria and Policies:
- Restricted Access vs. General Benefit
 - Specific restriction criteria
-

Objective 2: Impact of different drug reimbursement schemes for drugs for treatment of ADHD

Study Design:	<u>Design:</u> Literature review <u>Data sources:</u> Medline, EMBASE, Cochrane Collection, Grey literature
Study Population:	Stimulants and non-stimulants for treatment of ADHD
Intervention:	Various drug reimbursement schemes, including general benefits, step therapy, special authorization
Outcome(s) of Interest:	Indirect/direct measurements of clinical outcomes, patient satisfaction, quality of life, utilization and/or costs, functionality at work, days of productivity at work

Objective 3: Guidelines for use of stimulants and non-stimulants for treatment of ADHD in adults

Study Design:	<u>Design:</u> Literature review <u>Data sources:</u> Medline, EMBASE, Cochrane Collection, Grey literature
Study Population:	Stimulants and non-stimulants for treatment of ADHD in adults
Intervention:	Guidelines/recommendations for the use of stimulants and non-stimulants for treatment of ADHD in adults
Outcome(s) of Interest:	Published guidelines by various organizations: CADDRA (2011), NICE (2008)